48 Participants Needed

Aticaprant + Antidepressant for Depression

(VENTURA-5 Trial)

Recruiting at 94 trial locations
SC
Overseen ByStudy Contact
Age: 18 - 65
Sex: Any
Trial Phase: Phase 3
Sponsor: Janssen Research & Development, LLC
Must be taking: SSRI, SNRI
Stay on Your Current MedsYou can continue your current medications while participating
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor \[SSRI\] or serotonin-norepinephrine reuptake inhibitor \[SNRI\]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant.

Do I need to stop my current medications to join the trial?

The trial does not specify if you need to stop your current medications, but it involves taking aticaprant in addition to your current antidepressant (SSRI or SNRI). It seems you will continue your existing antidepressant therapy while participating.

How does the drug Aticaprant + Antidepressant for Depression differ from other treatments for depression?

The treatment combines Aticaprant, a novel drug, with traditional antidepressants, potentially offering a unique mechanism of action by targeting different pathways in the brain compared to standard antidepressants alone. This combination may provide enhanced efficacy for patients who do not respond adequately to existing antidepressant therapies.12345

Who Is on the Research Team?

JR

Janssen Research & Development, LLC Clinical Trial

Principal Investigator

Janssen Research & Development, LLC

Are You a Good Fit for This Trial?

This trial is for adults with Major Depressive Disorder who still feel a loss of interest and pleasure despite being on antidepressants. They should have had some improvement with aticaprant added to their treatment. People can't join if they have other mental health conditions, are pregnant or breastfeeding, or are at risk of suicide.

Inclusion Criteria

I have been diagnosed with depression without experiencing psychosis.
My health is stable as confirmed by recent medical exams.
My recent lab tests show that my health is stable.
See 1 more

Exclusion Criteria

History of moderate-to-severe substance use disorder within 6 months before screening
I have not followed my antidepressant treatment as prescribed.
My depression hasn't improved after trying 2 different antidepressants.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Open-label Treatment

Participants receive open-label treatment with adjunctive aticaprant to achieve a stable response

16 weeks

Double-blind Treatment Maintenance

Participants are randomized to receive either aticaprant or placebo in addition to their antidepressant therapy to prevent relapse

Up to 2 years 2 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Aticaprant
Trial Overview The study tests whether adding Aticaprant to regular antidepressant therapy (SSRI or SNRI) prevents the return of depression symptoms better than a placebo in those who've seen initial improvements but still struggle with anhedonia.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Placebo Group
Group I: AticaprantExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Janssen Research & Development, LLC

Lead Sponsor

Trials
1,022
Recruited
6,408,000+
Joaquin Duato profile image

Joaquin Duato

Janssen Research & Development, LLC

Chief Executive Officer since 2022

MBA from ESADE, Master of International Management from Thunderbird School of Global Management

Dr. Jijo James, MD profile image

Dr. Jijo James, MD

Janssen Research & Development, LLC

Chief Medical Officer since 2014

MD from St. Johns Medical College, MPH from Columbia University

Published Research Related to This Trial

A large cohort study found that patients with gastric cancer who used antidepressants (ATDs) after surgery had improved overall survival (OS), with a clear dose-dependent relationship indicating that higher ATD use correlated with longer survival times.
The study analyzed data from patients diagnosed between 1999 and 2008, revealing that those taking higher cumulative doses of ATDs had significantly lower hazard ratios for mortality, suggesting that ATDs may have a beneficial effect on survival outcomes in gastric cancer patients.
Antidepressants use is associated with overall survival improvement of patients with gastric cancer after surgery and adjuvant chemotherapy in Taiwan: A large population-based cohort study.Shih, WT., Yang, PR., Chen, KJ., et al.[2023]
In a study of 12 patients with resectable advanced gastric cancer, the combination of S-1 and CDDP as neoadjuvant chemotherapy showed a high preoperative response rate of 75%, indicating its potential effectiveness.
The treatment was well-tolerated with no severe adverse reactions reported, but further evaluation in clinical trials is necessary to determine the long-term survival benefits of this chemotherapy regimen.
[S-1/CDDP combined neoadjuvant chemotherapy and surgical resection for advanced gastric cancer. Analysis of 12 patients with lymph node metastasis in Saitama Red Cross Hospital].Nakamura, Y., Nakagawa, K., Fujita, M., et al.[2013]
In a study of 321 patients with advanced stomach cancer, the intensive therapy group experienced more adverse reactions, including significant decreases in blood cell counts and higher rates of nausea and vomiting compared to the standard therapy group.
Despite the increased side effects in the intensive therapy group, there was no significant difference in 3-year survival or disease-free survival rates between the intensive and standard therapy groups.
[Interim report of JFMTC study no. 20 on the effectiveness of high dose CDDP plus 5-FU regimen as an adjuvant therapy for far-advanced cancer of the stomach].Toge, T., Fujita, M., Hirata, K., et al.[2013]

Citations

Antidepressants use is associated with overall survival improvement of patients with gastric cancer after surgery and adjuvant chemotherapy in Taiwan: A large population-based cohort study. [2023]
[S-1/CDDP combined neoadjuvant chemotherapy and surgical resection for advanced gastric cancer. Analysis of 12 patients with lymph node metastasis in Saitama Red Cross Hospital]. [2013]
[Interim report of JFMTC study no. 20 on the effectiveness of high dose CDDP plus 5-FU regimen as an adjuvant therapy for far-advanced cancer of the stomach]. [2013]
[Three successful cases with CPT-11 + CDDP chemotherapy where S-1 failed to respond to recurrent gastric cancer]. [2018]
Phase I/II study of paclitaxel + carboplatin for refractory or recurrent non-small cell lung cancer. [2015]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security